[4-[4-(4-Hydroxyphenyl)hex-3-en-3-yl]phenyl] phosphono hydrogen phosphate (BioDeep_00000183721)
human metabolite blood metabolite
代谢物信息卡片
化学式: C18H22O8P2 (428.079)
中文名称:
谱图信息:
最多检出来源 () %
分子结构信息
SMILES: CCC(=C(CC)C1=CC=C(OP(O)(=O)OP(O)(O)=O)C=C1)C1=CC=C(O)C=C1
InChI: InChI=1S/C18H22O8P2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(12-8-14)25-28(23,24)26-27(20,21)22/h5-12,19H,3-4H2,1-2H3,(H,23,24)(H2,20,21,22)
描述信息
同义名列表
4 个代谢物同义名
{[hydroxy({4-[4-(4-hydroxyphenyl)hex-3-en-3-yl]phenoxy})phosphoryl]oxy}phosphonic acid; [hydroxy(4-[4-(4-hydroxyphenyl)hex-3-en-3-yl]phenoxy)phosphoryl]oxyphosphonic acid; [4-[4-(4-Hydroxyphenyl)hex-3-en-3-yl]phenyl] phosphono hydrogen phosphoric acid; [4-[4-(4-Hydroxyphenyl)hex-3-en-3-yl]phenyl] phosphono hydrogen phosphate
相关代谢途径
Reactome()
BioCyc()
PlantCyc()
代谢反应
个相关的代谢反应过程信息。
Reactome()
BioCyc()
WikiPathways()
Plant Reactome()
INOH()
PlantCyc()
COVID-19 Disease Map()
PathBank()
PharmGKB()
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Taku Naiki, Takehiko Okamura, Noriyasu Kawai, Hiroshi Sakagami, Yasuyuki Yamada, Keiji Fujita, Hidetoshi Akita, Yoshihiro Hashimoto, Keiichi Tozawa, Kenjiro Kohri. Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients.
Asian Pacific journal of cancer prevention : APJCP.
2009 Jan; 10(1):71-4. doi:
. [PMID: 19469628] - Shogo Inoue, Kiyotaka Oka, Teruo Araki, Akira Yano, Takatoshi Tacho, Motohiro Fujii, Kuniharu Kimoto, Michiyasu Murakami, Yumi Ohshiro. [Neuroendocrine carcinoma of the prostate effectively treated by cisplatin and irinotecan--a case report].
Gan to kagaku ryoho. Cancer & chemotherapy.
2007 Aug; 34(8):1323-5. doi:
. [PMID: 17687224] - Shinya Yamamoto, Jyunji Yonese, Satoru Kawakami, Tetsuro Tsukamoto, Yuhei Ohkubo, Manabu Tatokoro, Iwao Fukui. Possibility of recovery of estrogen sensitivity following high-dose glucocorticoid therapy in a patient with hormone-refractory prostate cancer.
International journal of clinical oncology.
2006 Aug; 11(4):326-8. doi:
10.1007/s10147-006-0570-9. [PMID: 16937308] - H Koike, K Ito, Y Takezawa, T Oyama, H Yamanaka, K Suzuki. Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer.
British journal of cancer.
2005 Apr; 92(8):1538-44. doi:
10.1038/sj.bjc.6602520. [PMID: 15846301] - Norihiro Hayashi, Tetsuro Wada, Isao Ikemoto, Yukihiko Oishi, Hidenori Suzuki, Masataka Ueda. [Decrease in anticoagulant factors in patients with prostate cancer treated with diethylstilbestrol diphosphate].
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.
2003 Mar; 94(3):420-7. doi:
10.5980/jpnjurol1989.94.420. [PMID: 12710076] - Shinichi Usui, Kazuhiro Suzuki, Hidetoshi Yamanaka, Takamitsu Nakano, Katsuyuki Nakajima, Yukichi Hara, Mitsuyo Okazaki. Estrogen treatment of prostate cancer increases triglycerides in lipoproteins as demonstrated by HPLC and immunoseparation techniques.
Clinica chimica acta; international journal of clinical chemistry.
2002 Mar; 317(1-2):133-43. doi:
10.1016/s0009-8981(01)00768-9. [PMID: 11814468] - M Kuriyama, Y Takahashi, M Sahashi, Y Ono, T Tanaka, H Shimizu, S Ohshima. Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer.
Japanese journal of clinical oncology.
2001 Jan; 31(1):18-24. doi:
10.1093/jjco/hye008. [PMID: 11256836]
